<DOC>
	<DOC>NCT02612649</DOC>
	<brief_summary>The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.</brief_summary>
	<brief_title>Special Drug Use Surveillance of Irribow in Female Patients</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>Female patients with diarrheapredominant irritable bowel syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>YM060</keyword>
	<keyword>Ramosetron</keyword>
	<keyword>Survey</keyword>
</DOC>